MX2020008387A - Usos terapeuticos de agonistas glp1r. - Google Patents

Usos terapeuticos de agonistas glp1r.

Info

Publication number
MX2020008387A
MX2020008387A MX2020008387A MX2020008387A MX2020008387A MX 2020008387 A MX2020008387 A MX 2020008387A MX 2020008387 A MX2020008387 A MX 2020008387A MX 2020008387 A MX2020008387 A MX 2020008387A MX 2020008387 A MX2020008387 A MX 2020008387A
Authority
MX
Mexico
Prior art keywords
glp1r
certain
aspects
disclosure provides
agonists
Prior art date
Application number
MX2020008387A
Other languages
English (en)
Spanish (es)
Inventor
Jennifer L R Freeman
Lopez Maria Carmen Valcarce
Original Assignee
Vtv Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vtv Therapeutics Llc filed Critical Vtv Therapeutics Llc
Publication of MX2020008387A publication Critical patent/MX2020008387A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2020008387A 2018-05-08 2019-05-01 Usos terapeuticos de agonistas glp1r. MX2020008387A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862668384P 2018-05-08 2018-05-08
PCT/US2019/030110 WO2019217165A1 (en) 2018-05-08 2019-05-01 Therapeutic uses of glp1r agonists

Publications (1)

Publication Number Publication Date
MX2020008387A true MX2020008387A (es) 2020-12-11

Family

ID=66484210

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008387A MX2020008387A (es) 2018-05-08 2019-05-01 Usos terapeuticos de agonistas glp1r.

Country Status (9)

Country Link
US (2) US20210023072A1 (enExample)
EP (1) EP3790549A1 (enExample)
JP (2) JP2021523877A (enExample)
KR (2) KR20260036616A (enExample)
AU (2) AU2019266114A1 (enExample)
CA (1) CA3090823A1 (enExample)
MX (1) MX2020008387A (enExample)
SG (1) SG11202007966UA (enExample)
WO (1) WO2019217165A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20221040A1 (es) 2019-10-25 2022-06-17 Gilead Sciences Inc Compuestos moduladores de glp-1r
CA3168543A1 (en) 2020-01-29 2021-08-05 Gilead Sciences, Inc. Glp-1r modulating compounds
EP4141008A4 (en) * 2020-04-01 2024-04-17 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. PHARMACEUTICALLY ACCEPTABLE ACID SALT OF GLP-1 RECEPTOR AGONIST FREE BASE, AND PREPARATION METHOD THEREFOR
JP2023528565A (ja) * 2020-04-01 2023-07-05 ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー．，エルティーディー． Ｇｌｐ－１受容体アゴニストの結晶形ａおよびその調製法
US20230348412A1 (en) * 2020-05-28 2023-11-02 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Method for preparing glp-1 receptor agonist
TW202227455A (zh) * 2020-09-21 2022-07-16 美商維特衛治療有限責任公司 異喹啉衍生物的無定形形式
WO2022109182A1 (en) 2020-11-20 2022-05-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
EP4304711A1 (en) 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
WO2022192430A1 (en) 2021-03-11 2022-09-15 Gilead Sciences, Inc. Glp-1r modulating compounds
PL4271672T3 (pl) 2021-04-21 2026-04-20 Gilead Sciences, Inc. Karboksybenzimidazolowe związki modulujące glp-1r
KR102920994B1 (ko) 2024-05-20 2026-02-02 (주)인벤티지랩 오르포르글리포론 또는 이의 약학적으로 허용되는 염을 포함하는 마이크로 입자 및 이의 제조 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002534512A (ja) * 1999-01-15 2002-10-15 ノボ ノルディスク アクティーゼルスカブ 非ペプチドｇｌｐ−１アゴニスト
KR101616737B1 (ko) 2008-03-07 2016-05-02 브이티브이 테라퓨틱스 엘엘씨 당뇨병 치료를 위한 옥사디아조안트라센 화합물
CA2757084C (en) 2009-03-30 2017-08-29 Transtech Pharma, Inc. Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
WO2011031620A1 (en) * 2009-09-11 2011-03-17 Transtech Pharma, Inc. Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same
JP2015510947A (ja) * 2012-03-22 2015-04-13 トランステック・ファーマ，エルエルシー 小分子ｇｌｐ１ｒアゴニストのトリス（ヒドロキシメチル）アミノメタン塩ならびにその医薬組成物および使用
WO2014113357A1 (en) * 2013-01-17 2014-07-24 Transtech Pharma, Llc Combinations of a glp1r agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders

Also Published As

Publication number Publication date
AU2019266114A1 (en) 2020-08-27
US20210023072A1 (en) 2021-01-28
AU2025201814A1 (en) 2025-04-03
TW202015683A (zh) 2020-05-01
KR20260036616A (ko) 2026-03-17
JP2021523877A (ja) 2021-09-09
WO2019217165A1 (en) 2019-11-14
JP2024112903A (ja) 2024-08-21
US20250325536A1 (en) 2025-10-23
EP3790549A1 (en) 2021-03-17
KR20210005843A (ko) 2021-01-15
SG11202007966UA (en) 2020-11-27
CA3090823A1 (en) 2019-11-14

Similar Documents

Publication Publication Date Title
SA521431209B1 (ar) مواد مساعدة لمستقبل الببتيد الشبيه بالجلوكاجون 1
CR20230330A (es) Agonistas del receptor gpcr, composiciones farmaceuticas que los comprenden y métodos para su uso
PH12019501216A1 (en) New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists
NZ732000A (en) Gip and glp-1 co-agonist compounds
TN2017000148A1 (en) Co-agonists of the glucagon and glp-1 receptors
MX2024010346A (es) Compuestos como agonistas de glp-1r.
MX2019006427A (es) Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip.
MY191321A (en) Glucagon and glp-1 co-agonists for the treatment of obesity
EA201001801A1 (ru) Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения
MX2018000362A (es) Derivados de exendina-4 como agonistas peptidicos duales selectivos de los receptores de glp-1/glucagon.
EP3575314A3 (en) Glucagon derivatives
MX2023012465A (es) Regimen de dosificacion de anti-ifnar1 para inyeccion subcutanea.
MX2009013779A (es) Uso de agonistas de tlr y/o interferonas tipo 1 para aliviar la toxicidad de los regimenes terapeuticos de agonistas de tnf-r.
SA522432563B1 (ar) نظير ببتيد أوكسينتو موديولين معالج بأسيل
NZ786543A (en) Compounds active towards nuclear receptors
PH12021551243A1 (en) Oxyntomodulin peptide analog formulations
MX2024002845A (es) Nuevos peptidos como agonistas potentes y selectivos del receptor de gip.
MX2015008555A (es) Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos.
MX2024004333A (es) Usos terapeuticos de activadores de glucoquinasa en combinacion con insulina o analogos de insulinas.
EA202192296A1 (ru) Терапевтическое применение дулаглутида
MX2025007327A (es) Nuevo triple agonista de los receptores glp-1/gip/glucagon y composicion farmaceutica para evitar o tratar la obesidad que lo contiene
MX2024004398A (es) Peptidos y fragmentos para tratar diabetes y enfermedades metabolicas asociadas.
AU2019253577A1 (en) Oxytocin compositions and methods of use
PH12021553215A1 (en) Pharmaceutical compositions for glucagon and glp-1 co-agonist peptides
MX2025008457A (es) Variantes recombinantes de las proteinas r-espondina y su uso